<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109707</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107A2101</org_study_id>
    <nct_id>NCT00109707</nct_id>
  </id_info>
  <brief_title>A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies</brief_title>
  <official_title>A Phase IA/II Multicenter, Dose-escalation Study of Oral AMN107 on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant/Intolerant CML in Chronic or Accelerated Phase or Blast Crisis, Relapsed/Refractory Ph+ ALL, and Other Hematologic Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the efficacy, safety, tolerability, biologic activity,&#xD;
      and pharmacokinetics of AMN107 in six groups of patients with one of the following&#xD;
      conditions:&#xD;
&#xD;
      Relapsed/refractory Ph+ Acute lymphoblastic leukemia (ALL) (arm 1)&#xD;
&#xD;
      Group A - Imatinib failure only (arms 2, 3 and 4)&#xD;
&#xD;
        -  imatinib-resistant or intolerant CML - Chronic Phase (CP)&#xD;
&#xD;
        -  imatinib-resistant or intolerant CML - Accelerated Phase (AP)&#xD;
&#xD;
        -  imatinib-resistant or intolerant CML - Blast Crisis (BC)&#xD;
&#xD;
      Group B - Imatinib and other TKI failure (arms 2, 3 and 4)&#xD;
&#xD;
        -  imatinib-resistant or intolerant CML - Chronic Phase (CP)&#xD;
&#xD;
        -  imatinib-resistant or intolerant CML - Accelerated Phase (AP)&#xD;
&#xD;
        -  imatinib-resistant or intolerant CML - Blast Crisis (BC)&#xD;
&#xD;
      Hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL) (arm 5)&#xD;
&#xD;
      Systemic mastocytosis (Sm) (arm 6)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2005</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Major Cytogenetic Response (MCyR)</measure>
    <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
    <description>Major Cytogenetic Response (MCyR) is defined as Complete Cytogenetic Response (CCyR: 0% Ph-chromosome-positive cells in metaphase in bone marrow) or Partial Cytogenetic Response (PCyR: 1-35% Ph-chromosome-positive cells in metaphase in bone marrow).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Confirmed Overall Hematological Response (Phase II)</measure>
    <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
    <description>Hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count &lt;10 x 109/L, Platelet count &lt;450 x 109/L, Basophils &lt;5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes &lt; 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).&#xD;
Hematological response was a primary outcome measure for Arm CML-AP with prior imatinib only.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Major Cytogenetic Responses (Phase II)</measure>
    <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
    <description>Cytogenetic responses (CyRs) in CML are based on the percentage of Ph+ metaphases in bone marrow; a value of 0% Ph+ metaphases defines a complete cytogenetic response (CCyR) and &gt;0% to 35% defines a major cytogenetic response (MCyR). Achievement of CCyR is associated with a significant survival advantage in participants with CML-CP. MCyR was categorized as either CCyR or partial cytogenetic response (PCyR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Complete Hematologic Response (Phase II)</measure>
    <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
    <description>A Complete Hematologic Response (CHR) is obtained when all the following criteria are met: WBC ≤ institutional ULN; platelets ≤ 450,000/mm3; ≤20% basophils in peripheral blood; no blasts or promyelocytes in PB cells; &lt; 5% myelocytes plus metamyelocytes in PB cells; no extra-medullary involvement including no hepatomegaly or splenomegaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With (MMR) Major Molecular Response (Phase II)</measure>
    <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
    <description>MMR was defined for participants who demonstrated a reduction in BCR-ABL/control gene % transcripts to ≤0.1% based on international scale. The control gene used may have been either BCR or ABL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP) (Phase II)</measure>
    <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
    <description>Time to Progression was defined as the time from the start of nilotinib to the earliest date of Disease Progression (PD), discontinuation due to PD or death.&#xD;
Disease progression was defined as an increase in the number of circulating leukemic cells via cytogenetic assessment using real-time quantitative reverse transcriptase polymerase chain reaction (PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (Phase II)</measure>
    <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
    <description>OS was calculated for all participants as the time between the start of nilotinib and death. Participants were followed for survival after discontinuation, every 3 months, and were included in the analysis of OS. Censoring was at the date of the last contact for discontinued participants and followed up for survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events and Serious Adverse Events to Evaluate Long Term Safety</measure>
    <time_frame>From First Participant First Visit to Last Participant Last Visit (Approximately 7.5 years)</time_frame>
    <description>Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">507</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)</condition>
  <condition>Hypereosinophilic Syndrome</condition>
  <condition>Systemic Mastocytosis</condition>
  <arm_group>
    <arm_group_label>CML-CP With Prior Imatinib Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib-resistant / intolerant PH+ CML-CP patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CML-AP With Prior Imatinib Onl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib-resistant / intolerant PH+ CML-AP patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CML-CP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Imatinib-resistant / intolerant PH+ CML-CP patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <arm_group_label>CML-AP With Prior Imatinib Onl</arm_group_label>
    <arm_group_label>CML-CP</arm_group_label>
    <arm_group_label>CML-CP With Prior Imatinib Only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Main inclusion criteria include:&#xD;
&#xD;
          -  Patients with CML in blast crisis, CML in accelerated phase defined as never in blast&#xD;
             crisis phase, or CML in chronic phase defined as never been in blast crisis phase or&#xD;
             accelerated phase who have: *developed progressive disease during therapy with at&#xD;
             least 600 mg of imatinib per day, -OR- *patients with CML on imatinib therapy, at any&#xD;
             dose, developing progressive disease and the presence of a genetic mutation likely to&#xD;
             result in imatinib resistance -OR- *have developed an intolerance to imatinib&#xD;
&#xD;
          -  Relapsed or refractory Ph+ ALL&#xD;
&#xD;
          -  Hypereosinophilic syndrome/chronic eosinophilic leukemia.&#xD;
&#xD;
          -  Systemic mastocytosis who have a clinical indication for treatment.&#xD;
&#xD;
          -  Prior imatinib therapy for patients with Ph+ ALL, HES/CEL and SM is permitted but is&#xD;
             not required&#xD;
&#xD;
          -  CML patients who have been treated with an investigational tyrosine kinase inhibitor&#xD;
             who otherwise meet the definition of imatinib-resistance or intolerance are eligible&#xD;
&#xD;
          -  Written informed consent prior to any study procedures being performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Impaired cardiac function&#xD;
&#xD;
          -  Patients with severe/chronic or uncontrolled medical conditions (including but not&#xD;
             limited to diabetes, infections, GI impairment, CNS infiltration, liver and kidney&#xD;
             disease)&#xD;
&#xD;
          -  Prior and concomitant use of certain medications (including but not limited to&#xD;
             warfarin, chemotherapy, hematopoietic colony-stimulating growth factors, medications&#xD;
             that can affect electrocardiogram test results, other investigational drugs )&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Patients with a history of another primary malignancy that is currently clinically&#xD;
             significant or currently requires active intervention.&#xD;
&#xD;
          -  Patients unwilling to comply with the protocol.&#xD;
&#xD;
          -  Known diagnosis of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticlas</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute Dept.of H. Lee Moffitt</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center Dept. of U. of Chicago Hosp(3)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago Divisionof Hematology/Oncology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Institute Dept of Indiana Blood&amp;Mar (2)</name>
      <address>
        <city>Beech Grove</city>
        <state>Indiana</state>
        <zip>46107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Div.of Hematologic Malignancie</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System Clinical Trials Office</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute Rosewell SC</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Jones Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center, Clinical Trials Center Investigational Drug Services</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center/University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haine-saint-Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vejle</city>
        <zip>DK-7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>HUS Helsinki</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limoges cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes</city>
        <zip>35019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt/M</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68169</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pescara</city>
        <state>PE</state>
        <zip>65124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orbassano</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hwasun-gun</city>
        <state>Jeollanam-do</state>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taegu</city>
        <zip>700 - 721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-776</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-367</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niaosong Township</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow - Scotland</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=9963</url>
    <description>Results for CAMN107A2101 on the Novartis Clinical Trials Website</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 2, 2005</study_first_submitted>
  <study_first_submitted_qc>May 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2005</study_first_posted>
  <results_first_submitted>April 28, 2021</results_first_submitted>
  <results_first_submitted_qc>June 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2021</results_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML in blast crisis</keyword>
  <keyword>CML in chronic phase</keyword>
  <keyword>CML in accelerated phase</keyword>
  <keyword>Gleevec resistance</keyword>
  <keyword>Gleevec intolerant</keyword>
  <keyword>Gleevec and CML</keyword>
  <keyword>imatinib resistance</keyword>
  <keyword>imatinib intolerant</keyword>
  <keyword>Hypereosinophilic Syndrome</keyword>
  <keyword>Systemic Mastocytosis</keyword>
  <keyword>Chronic eosinophilic syndrome</keyword>
  <keyword>Philadelphia chromosome positive acute lymphoblastic leukemia</keyword>
  <keyword>HES</keyword>
  <keyword>CEL</keyword>
  <keyword>CML</keyword>
  <keyword>SM</keyword>
  <keyword>Ph+ ALL refractory to standard therapy</keyword>
  <keyword>Ph+ALL relapsed</keyword>
  <keyword>AMN107A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Systemic</mesh_term>
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 100 centers in 22 countries.</recruitment_details>
      <pre_assignment_details>A total of 507 participants were randomized in the core study, out of which 136 participants entered the extension study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CML-CP With Prior Imatinib Only</title>
          <description>Adult participants PH+ CML-CP ( Chronic Phase Chronic Myeloid Leukemia) without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
        </group>
        <group group_id="P2">
          <title>CML-AP With Prior Imatinib Only</title>
          <description>Adult participants PH+ CML-AP (Accelerated Phase Chronic Myeloid Leukemia) without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
        </group>
        <group group_id="P3">
          <title>CML-CP</title>
          <description>Adult participants PH+ CML-CP in addition to prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="321"/>
                <participants group_id="P2" count="137"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Extension Study</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="129"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued in core study without entering the extension study</title>
              <participants_list>
                <participants group_id="P1" count="215"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal laboratory values</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CML-CP With Prior Imatinib Only</title>
          <description>Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
        </group>
        <group group_id="B2">
          <title>CML-AP With Prior Imatinib Only</title>
          <description>Adult participants PH+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
        </group>
        <group group_id="B3">
          <title>CML-CP</title>
          <description>Adult participants PH+ CML-CP in addition to prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="321"/>
            <count group_id="B2" value="137"/>
            <count group_id="B3" value="49"/>
            <count group_id="B4" value="507"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;35 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥35 to &lt;55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥55 to &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="245"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Major Cytogenetic Response (MCyR)</title>
        <description>Major Cytogenetic Response (MCyR) is defined as Complete Cytogenetic Response (CCyR: 0% Ph-chromosome-positive cells in metaphase in bone marrow) or Partial Cytogenetic Response (PCyR: 1-35% Ph-chromosome-positive cells in metaphase in bone marrow).</description>
        <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
        <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>CML-CP With Prior Imatinib Only</title>
            <description>Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
          <group group_id="O2">
            <title>CML-AP With Prior Imatinib Only</title>
            <description>Adult participants PH+ CML-AP (Accelerated Phase Chronic Myeloid Leukemia) without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
          <group group_id="O3">
            <title>CML-CP</title>
            <description>Adult participants Ph+ CML-CP in addition to prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Major Cytogenetic Response (MCyR)</title>
          <description>Major Cytogenetic Response (MCyR) is defined as Complete Cytogenetic Response (CCyR: 0% Ph-chromosome-positive cells in metaphase in bone marrow) or Partial Cytogenetic Response (PCyR: 1-35% Ph-chromosome-positive cells in metaphase in bone marrow).</description>
          <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Confirmed Overall Hematological Response (Phase II)</title>
        <description>Hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count &lt;10 x 109/L, Platelet count &lt;450 x 109/L, Basophils &lt;5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes &lt; 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).&#xD;
Hematological response was a primary outcome measure for Arm CML-AP with prior imatinib only.</description>
        <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
        <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CML-AP With Prior Imatinib Only</title>
            <description>Adult participants Ph+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Confirmed Overall Hematological Response (Phase II)</title>
          <description>Hematologic response is defined as the percentage of participants in complete hematologic response (defined as the following present for at least 4 weeks: WBC count &lt;10 x 109/L, Platelet count &lt;450 x 109/L, Basophils &lt;5%, No blasts and promyelocytes in peripheral blood, Myelocytes + metamyelocytes &lt; 5% in peripheral blood, No evidence of extramedullary disease, including spleen and liver).&#xD;
Hematological response was a primary outcome measure for Arm CML-AP with prior imatinib only.</description>
          <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Major Cytogenetic Responses (Phase II)</title>
        <description>Cytogenetic responses (CyRs) in CML are based on the percentage of Ph+ metaphases in bone marrow; a value of 0% Ph+ metaphases defines a complete cytogenetic response (CCyR) and &gt;0% to 35% defines a major cytogenetic response (MCyR). Achievement of CCyR is associated with a significant survival advantage in participants with CML-CP. MCyR was categorized as either CCyR or partial cytogenetic response (PCyR).</description>
        <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
        <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>CML-CP With Prior Imatinib Only</title>
            <description>Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
          <group group_id="O2">
            <title>CML-AP With Prior Imatinib Only</title>
            <description>Adult participants Ph+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
          <group group_id="O3">
            <title>CML-CP</title>
            <description>Adult participants Ph+ CML-CP in addition to prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Major Cytogenetic Responses (Phase II)</title>
          <description>Cytogenetic responses (CyRs) in CML are based on the percentage of Ph+ metaphases in bone marrow; a value of 0% Ph+ metaphases defines a complete cytogenetic response (CCyR) and &gt;0% to 35% defines a major cytogenetic response (MCyR). Achievement of CCyR is associated with a significant survival advantage in participants with CML-CP. MCyR was categorized as either CCyR or partial cytogenetic response (PCyR).</description>
          <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Complete Hematologic Response (Phase II)</title>
        <description>A Complete Hematologic Response (CHR) is obtained when all the following criteria are met: WBC ≤ institutional ULN; platelets ≤ 450,000/mm3; ≤20% basophils in peripheral blood; no blasts or promyelocytes in PB cells; &lt; 5% myelocytes plus metamyelocytes in PB cells; no extra-medullary involvement including no hepatomegaly or splenomegaly.</description>
        <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
        <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>CML-CP With Prior Imatinib Only</title>
            <description>Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
          <group group_id="O2">
            <title>CML-AP With Prior Imatinib Only</title>
            <description>Adult participants Ph+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
          <group group_id="O3">
            <title>CML-CP</title>
            <description>Adult participants Ph+ CML-CP in addition to prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Complete Hematologic Response (Phase II)</title>
          <description>A Complete Hematologic Response (CHR) is obtained when all the following criteria are met: WBC ≤ institutional ULN; platelets ≤ 450,000/mm3; ≤20% basophils in peripheral blood; no blasts or promyelocytes in PB cells; &lt; 5% myelocytes plus metamyelocytes in PB cells; no extra-medullary involvement including no hepatomegaly or splenomegaly.</description>
          <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="76"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With (MMR) Major Molecular Response (Phase II)</title>
        <description>MMR was defined for participants who demonstrated a reduction in BCR-ABL/control gene % transcripts to ≤0.1% based on international scale. The control gene used may have been either BCR or ABL.</description>
        <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
        <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication.&#xD;
Major molecular response was not an efficacy variable for participants who received the CML-CP with prior imatinib and other TKI (Group B E8)</population>
        <group_list>
          <group group_id="O1">
            <title>CML-CP With Prior Imatinib Only</title>
            <description>Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
          <group group_id="O2">
            <title>CML-AP With Prior Imatinib Only</title>
            <description>Adult participants Ph+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With (MMR) Major Molecular Response (Phase II)</title>
          <description>MMR was defined for participants who demonstrated a reduction in BCR-ABL/control gene % transcripts to ≤0.1% based on international scale. The control gene used may have been either BCR or ABL.</description>
          <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication.&#xD;
Major molecular response was not an efficacy variable for participants who received the CML-CP with prior imatinib and other TKI (Group B E8)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="299"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP) (Phase II)</title>
        <description>Time to Progression was defined as the time from the start of nilotinib to the earliest date of Disease Progression (PD), discontinuation due to PD or death.&#xD;
Disease progression was defined as an increase in the number of circulating leukemic cells via cytogenetic assessment using real-time quantitative reverse transcriptase polymerase chain reaction (PCR).</description>
        <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
        <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication.&#xD;
Time to progression was not an efficacy variable for participants who received the CML-CP with prior imatinib and other TKI (Group B E8).</population>
        <group_list>
          <group group_id="O1">
            <title>CML-CP With Prior Imatinib Only</title>
            <description>Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
          <group group_id="O2">
            <title>CML-AP With Prior Imatinib Only</title>
            <description>Adult participants Ph+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP) (Phase II)</title>
          <description>Time to Progression was defined as the time from the start of nilotinib to the earliest date of Disease Progression (PD), discontinuation due to PD or death.&#xD;
Disease progression was defined as an increase in the number of circulating leukemic cells via cytogenetic assessment using real-time quantitative reverse transcriptase polymerase chain reaction (PCR).</description>
          <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication.&#xD;
Time to progression was not an efficacy variable for participants who received the CML-CP with prior imatinib and other TKI (Group B E8).</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="0.1" upper_limit="77.8"/>
                    <measurement group_id="O2" value="15.9" lower_limit="0.1" upper_limit="75.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) (Phase II)</title>
        <description>OS was calculated for all participants as the time between the start of nilotinib and death. Participants were followed for survival after discontinuation, every 3 months, and were included in the analysis of OS. Censoring was at the date of the last contact for discontinued participants and followed up for survival.</description>
        <time_frame>Up to End of the Treatment (Approximately 7.5 years)</time_frame>
        <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>CML-CP With Prior Imatinib Only</title>
            <description>Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
          <group group_id="O2">
            <title>CML-AP With Prior Imatinib Only</title>
            <description>Adult participants Ph+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
          <group group_id="O3">
            <title>CML-CP</title>
            <description>Adult participants Ph+ CML-CP in addition to prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) (Phase II)</title>
          <description>OS was calculated for all participants as the time between the start of nilotinib and death. Participants were followed for survival after discontinuation, every 3 months, and were included in the analysis of OS. Censoring was at the date of the last contact for discontinued participants and followed up for survival.</description>
          <population>Full Analysis Set (FAS): All participants who received at least one dose of study medication.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="77.93" upper_limit="NA">Median OS was not reached as there were an insufficient number of participants</measurement>
                    <measurement group_id="O2" value="47.54" lower_limit="38.24" upper_limit="64.30"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Median OS was not reached as there were an insufficient number of participants</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events and Serious Adverse Events to Evaluate Long Term Safety</title>
        <description>Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.</description>
        <time_frame>From First Participant First Visit to Last Participant Last Visit (Approximately 7.5 years)</time_frame>
        <population>Safety set: All participants who received at least one dose of study medication and had at least one post baseline safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>CML-CP With Prior Imatinib Only</title>
            <description>Adult participants PH+ CML-CP ( Chronic Phase Chronic Myeloid Leukemia) without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
          <group group_id="O2">
            <title>CML-AP With Prior Imatinib Only</title>
            <description>Adult participants PH+ CML-AP (Accelerated Phase Chronic Myeloid Leukemia) without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
          <group group_id="O3">
            <title>CML-CP</title>
            <description>Adult participants PH+ CML-CP in addition to prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events and Serious Adverse Events to Evaluate Long Term Safety</title>
          <description>Adverse events (AEs) were defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events (SAEs) were defined as any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgement of investigators represent significant hazards.</description>
          <population>Safety set: All participants who received at least one dose of study medication and had at least one post baseline safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="321"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serious Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From First Participant First Visit to Last Participant Last Visit (Approximately 7.5 years)</time_frame>
      <desc>Safety set: All participants who received at least one dose of study medication and had at least one post baseline safety assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>CML-CP With Prior Imatinib Only</title>
          <description>Adult participants PH+ CML-CP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
        </group>
        <group group_id="E2">
          <title>CML-AP With Prior Imatinib Only</title>
          <description>Adult participants Ph+ CML-AP without prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
        </group>
        <group group_id="E3">
          <title>CML-CP</title>
          <description>Adult participants Ph+ CML-CP in addition to prior TKI treatment with either resistant / intolerant to Imatinib received 400 mg Nilotinib orally twice daily up to the end of treatment (September-2012).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Catarac</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="319" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="104" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="321"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="137"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>NovartisPharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

